- Clinical Interests
- Depressive disorders
- Medical Education
- MD, University of Padua - Italy
- Residency, Massachusetts General Hospital|Residency, University of Padua - Italy
- Board Certifications
- Foreign Languages
- Boston: Massachusetts General Hospital
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna Behavioral Health
- Commonwealth Care Alliance
- Great-West Healthcare (formally One Health Plan)
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- OSW - Maine
- OSW - New Hampshire
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Senior Whole Health
- Tufts Health Plan
- United Behavioral Health
- United Behavioral Health - MGH
- Well Sense Pediatrics
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
- Provider Gender
Dr. Fava obtained his MD from the University of Padova School of Medicine where he completed residency training in endocrinology. He completed residency training in psychiatry at the MGH. He founded and was Director of the hospital’s Depression Clinical and Research Program (DCRP) from 1990 to 2014. In 2007, he founded and is now Executive Director of the MGH Psychiatry Clinical Trials Network and Institute (CTNI), the first academic CRO specialized in planning and coordination of multi-center clinical trials in psychiatry.
Under Dr. Fava’s direction, the DCRP became one of the most highly regarded depression programs in the country, a model for academic programs that link, in a bi-directional fashion, clinical and research work. Dr. Fava has been successful in obtaining funding as principal or co-principal investigator from both the National Institutes of Health and other sources for a total of more than $95,000,000. His prominence in the field is reflected in his role as the co-principal investigator of STAR*D, the largest research study ever conducted in the area of depression, and of the RAPID Network, the NIMH-funded series of studies of novel, rapidly-acting antidepressant therapies.
Dr. Fava is a world leader in the field of depression. He has authored or co-authored more than 800 original articles published in medical journals with international circulation, edited eight books, and published more than 50 chapters and over 600 abstracts.
Dr. Fava is Editor-in-Chief of MGH's
Mind, Mood & Memory newsletter. Click on the link for more information and a free trial issue.
Maurizio Fava, MD discusses why many people find it hard to remember names.
Two clinical trials of an investigational drug that targets the opioid system support its safety and effectiveness in reducing symptoms of major depression, when added to standard antidepressant treatment.
Maurizio Fava, MD, answers a patient's question about "catching up" on sleep.
A study led by Massachusetts General Hospital investigators identifies two subanesthetic dosage levels of the anesthetic drug ketamine that appear to provide significant symptom relief to patients with treatment-resistant depression.
Maurizio Fava, MD, answers a question about the long-term effects of football head injuries, and whether or not a patient should seek medical advice.
Both sides of the Bulfinch Tents were bustling May 24 at the annual Research Staff Appreciation Day event.
The 70th meeting of the MGH Scientific Advisory Committee focused on the MGH Research Institute, which was founded in 2015 as an organizational home for the more than 8,500 MGHers in 30 departments, centers and institutes who make up the largest hospital-based research program in the U.S.
Following the cutting of a ceremonial blue ribbon and an enthusiastic round of applause, the doors to the new MGH Translational and Clinical Research Center (TCRC) officially opened Nov. 30.
A clinical trial of an experimental drug for treatment-resistant major depression finds that modulation of the endogenous opioid system may improve the effectiveness of drugs that target the action of serotonin and related neurotransmitters.
A small clinical trial of a novel antidepressant that stimulates neurogenesis—the production of new brain cells—shows that the compound appears to be safe and may be effective against depression
Maurizio Fava, MD, executive vice chair of the Department of Psychiatry, was honored with the 2012 John T. Potts Jr., MD, Faculty Mentoring Award.
A new study will measure the ability of probiotic bacteria GanedenBC30 (Bacillus coagulans GB1-30, 6086) to help people diagnosed with irritable bowel syndrome (IBS) and major depressive disorder (MDD).
MGH Hotline 06.26.09 In General awards and honors
55 Fruit Street
Boston, MA 02114-2696